Inhalation products provide a patient-centric approach to delivering therapeutics directly to the lungs: with an estimated 800 million people suffering from chronic respiratory diseases worldwide, major potential for greater utility exists.
Inhaled biologics are being evaluated as an alternative to injections for treating rare and serious diseases. Experts touch on several challenges including making stable and safe formulations of inhaled biologics.
When designing drug-delivery devices, the patient must be at the centre of the development process. Nélio Drumond of Takeda Pharmaceuticals discusses how this patient-centric approach allows the design to maximise efficiency and efficacy.
Inhaled drugs are a viable means of targeting tobacco smoke-related diseases in the lungs: permeability is key to their successful delivery. This Commentary article explores the mechanisms by which drugs are delivered across cell membranes, as well as pertinent areas for present and future research.
This month, the discussion group debated the advantages and disadvantages of different types of inhalers. One key area of interest was current-day challenges with aerosol delivery, which could be addressed through smart inhalers and other innovative new devices.
Edited by Oliver Picken |
17 March 2022
Inhaled Drug Delivery
Search by Keyword
Filter by Subject Area
Filter by Content Type
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.